Javelin Pharmaceuticals to Present at The Rodman & Renshaw Techvest 8th Annual Healthcare Conference.CAMBRIDGE, Mass. -- Javelin Pharmaceuticals, Inc. (Amex: JAV) today announced that Dr. Daniel Carr, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. and CMO CMO
See: Collateralized mortgage obligation
See collateralized mortgage obligation (CMO). will present a corporate overview to investors at the Rodman & Renshaw Techvest 8th Annual Healthcare Conference being held November 6-8th 2006. Dr. Carr's presentation will take place on November 6, 2006 at 9:30 a.m. EST EST electroshock therapy.
electroshock therapy in the Holmes II room of the New York Palace
New York City
City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. .
With corporate headquarters in Cambridge, MA, Javelin applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the pain management market. The Company has two drug candidates in Phase III clinical development and one in late Phase II. One of these Phase III drug candidates, Dyloject, is currently under review for Marketing Authorization Application (MAA MAA
macroaggregated albumin ) approval in Europe. Previous clinical trials have demonstrated its safety and rapid onset of action onset of action Pharmacology The length of time needed for a medicine to become effective. See Therapeutic drug monitoring. . For additional information about Javelin, please visit the company's website at http://www.javelinpharmaceuticals.com or contact us directly.
Forward Looking Statement
This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our ability to obtain working capital, our ability to successfully develop and commercialize drug candidates, and competition from other pharmaceutical companies. JAV-G